Manner Carrie Eglinton
Manner Carrie Eglinton's purchase track record
How the stock did after each of Manner Carrie Eglinton's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/13/2026 | OSUR | $161K | +40.7% | +9.4% | +15.4% |
| 2/27/2025 | OSUR | $347K | -9.3% | +5.1% | +10.9% |
| 3/16/2022 | RGEN | $109K | -17.2% | +27.1% | -9.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Transaction History
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| OSUR | ▲ Buy | Open Market | 32,300 | $95K | 3/20/2026 | View on chart |
| OSUR | ▲ Buy | Open Market | 22,022 | $66K | 3/13/2026 | View on chart |
| OSUR | ▲ Buy | Grant | 355,464 | $0 | 3/2/2026 | View on chart |
| OSUR | ▲ Buy | Grant | 129,032 | $0 | 3/1/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 56,116 | $171K | 3/1/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 122,655 | $373K | 3/1/2026 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 47,249 | $137K | 6/4/2025 | View on chart |
| OSUR | ▲ Buy | Grant | 335,710 | $0 | 6/4/2025 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 146,000 | $423K | 6/4/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| OSUR | ▲ Buy | Grant | 462,414 | $0 | 3/1/2025 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 62,382 | $226K | 3/1/2025 | View on chart |
| OSUR | ▲ Buy | Open Market | 28,670 | $100K | 2/28/2025 | View on chart |
| OSUR | ▲ Buy | Open Market | 78,625 | $247K | 2/27/2025 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 401,618 | $1.9M | 6/4/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 701 | $0 | 5/16/2024 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 29,647 | $213K | 3/1/2024 | View on chart |
| OSUR | ▲ Buy | Grant | 260,688 | $0 | 3/1/2024 | View on chart |
| OSUR | ▼ Sell | Tax Withholding | 47,211 | $259K | 6/4/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 686 | $0 | 5/18/2023 | View on chart |
| OSUR | ▲ Buy | Grant | 258,065 | $0 | 3/1/2023 | View on chart |
| OSUR | ▲ Buy | Grant | 814,830 | $4.0M | 6/4/2022 | View on chart |
| OSUR | ▲ Buy | Grant | 325,932 | $1.6M | 6/4/2022 | View on chart |
| RGEN | ▲ Buy | Grant | 1,024 | $0 | 5/26/2022 | View on chart |
| RGEN | ▲ Buy | Open Market | 625 | $109K | 3/16/2022 | View on chart |
| DGX | ▲ Buy | Grant | 16,162 | $2.1M | 3/7/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 7,947 | $1.0M | 3/7/2022 | View on chart |
| DGX | ▲ Buy | Grant | 3,915 | $0 | 2/24/2022 | View on chart |
| DGX | ▲ Buy | Grant | 7,830 | $0 | 2/24/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 1,368 | $178K | 2/23/2022 | View on chart |
| DGX | ▼ Sell | Tax Withholding | 609 | $79K | 2/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition
Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.